Citations

Clear

135 citation(s) found for "Sim, SC".

Eating Disorders in Adolescents With a History of Obesity
Sim, Leslie , Lebow, Jocelyn , Billings, Marcie, Sim, Leslie a., Lebow, Jocelyn

Mayo Clinic

Pediatrics | September 10, 2013 | Volume: 132 | Issue: 4 | Pages: e1026-e1030

10.1542/peds.2012-3940 | PMID 24019418 Get It

Adolescent patients with obesity are at significant risk of developing an eating disorder (ED), yet due to their higher weight status their symptoms often go unrecognized and untreated. Although not widely known, individuals with a weight history in the overweight (BMI-for-age ≥85th percentile but <95th percentile, as defined by Centers for Disease Control and Prevention growth charts) or obese (BMI-for-age ≥95th percentile, as defined by the Centers for Disease Control and Prevention growth charts) range, represent a substantial portion of adolescents presenting for ED treatment. Given research that suggests that early intervention promotes the best chance of recovery, it is imperative that these children’s and adolescents’ ED symptoms are identified and that intervention is offered before the disease progresses. This report presents 2 examples of EDs that developed in the context of obese adolescents’ efforts to reduce their weight. Each case shows specific challenges in the identification of ED behaviors in adolescents with this weight history and the corresponding delay such teenagers experience accessing appropriate treatment.
Metastatic Tumors of the Foot and Ankle
Hattrup, Steven J. , Amadio, Peter C. , Sim, Franklin H. , Lombardi, Robert M.

Mayo Clinic

Foot & Ankle | March 3, 2013 | Volume: 8 | Issue: 5 | Pages: 243-247

10.1177/107110078800800503 | PMID 3366429 Get It

In a review of the Mayo Clinic files, 17 biopsy-proven cases of metastatic tumors of the foot and ankle were found; 4 additional cases were considered to have metastatic disease on the basis of clinical and radiographic evidence but no histological confirmation was available. Lung, kidney, and colon were the most common sites of the primary tumors. The patients survived as long as 28 months after discovery of the metastasis. Treatment consisted of individualized combinations of orthotics, surgery, and radiotherapy to maintain mobility. In 9 of these 17 cases, no primary lesion was identified at the time the metastasis was diagnosed. Metastatic tumors of the foot present special problems in diagnosis and management.
Effect of Granulocyte-Stimulating Factors on Marrow of Adult Patients with Musculoskeletal Malignancies: Incidence and MRI Findings
Hartman, Robert P. , Okuno, Scott H. , Sim, Franklin H. , Sundaram, Murali

Mayo Clinic

American Journal of Roentgenology | February 28, 2013 | Volume: 183 | Issue: 3 | Pages: 645-653

10.2214/ajr.183.3.1830645 | PMID 15333351 Get It

THE ASSOCIATION BETWEEN ANXIETY DISORDERS AND SUICIDAL BEHAVIORS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Kanwar, Amrit , Malik, Shaista , Sim, Leslie , Feldstein, David , Wang, Zhen , Murad, M. Hassan , Prokop, Larry J. , Murad, M Hassan , Wang, Zhen

Mayo Clinic

Depression and Anxiety | February 13, 2013 | Volume: No volume available | Issue: No issue available | Pages: n/a-n/a

10.1002/da.22074 | PMID 23408488 Get It

A Case of Q Fever Prosthetic Joint Infection and Description of an Assay for Detection of Coxiella burnetii
Tande, Aaron J. , Cunningham, Scott A. , Raoult, Didier , Sim, Franklin H. , Berbari, Elie F. , Patel, Robin , Tande, Aaron , Patel, Robin , Cunningham, Scott A

Mayo Clinic

Journal of Clinical Microbiology | October 18, 2012 | Volume: 51 | Issue: 1 | Pages: 66-69

10.1128/jcm.02352-12 | PMID 23077126 Get It

ABSTRACT We present the first published case of Coxiella burnetii prosthetic joint infection. Diagnosis was established with PCR and culture of periprosthetic tissue and synovial fluid (and serology). A novel PCR assay is described herein. Q fever should be considered in patients with prosthetic joint infection without an identified pathogen.
Multicentric Osteosarcoma
Corradi, Domenico , Wenger, Doris E. , Bertoni, Franco, Bacchini, Patrizia, Bosio, Silvia , Goldoni, Matteo , Unni, K. Krishnan, Sim, Franklin H. , Inwards, Carrie Y.

Mayo Clinic

American Journal of Clinical Pathology | October 26, 2011 | Volume: 136 | Issue: 5 | Pages: 799-807

10.1309/ajcp0v0oatkcnazp | PMID 22031320 Get It

Abstract Multicentric osteosarcoma (M-OGS) is characterized by multicentricity of osseous osteosarcomas, either synchronous or metachronous, without visceral involvement. The study’s purpose was to clinicopathologically and radiographically analyze 56 cases of M-OGS (22 synchronous and 34 metachronous). The distal femur was the most common site. Histologically, all tumors were high grade. Of 22 patients with synchronous M-OGS, 16 had 3 or more simultaneous tumors; the axial skeleton was involved in 14 (64%) of 22 cases. In metachronous M-OGS, the second malignancy occurred after a median of 22 months. Treatment was surgery, chemotherapy, radiotherapy, or a combination of these. Patients with metachronous osteosarcoma had a median survival longer than did patients with synchronous tumors. Overall, 8 long-term survivors were treated by aggressive surgery with wide margins (plus chemotherapy and/or radiotherapy). M-OGS combines multiple skeletal locations of high-grade conventional osteosarcomas and has a poor prognosis. Aggressive surgery may result in improved long-term survival, particularly in patients with metachronous disease.
Critical role for Syk in responses to vascular injury
André, Patrick, Morooka, Toshifumi, Sim, Derek , Abe, Keith , Lowell, Clifford A. , Nanda, Nisha, Delaney, Suzanne M., Siu, Gail, Yan, Yibing, Hollenbach, Stan, Gao, Huiyun, Wang, Yunmei, Nakajima, Kohsuke, Parikh, Sahil A. , Shi, Can , Owen, Whyte G., Sinha, Uma, Simon, Daniel I. , Pandey, Anjali , Phillips, David R.

Mayo Clinic

Blood | September 1, 2011 | Volume: 118 | Issue: 18 | Pages: 5000-5010

10.1182/blood-2011-06-360743 | PMID 21881044 Get It

AbstractAlthough current antiplatelet therapies provide potent antithrombotic effects, their efficacy is limited by a heightened risk of bleeding and failure to affect vascular remodeling after injury. New lines of research suggest that thrombosis and hemorrhage may be uncoupled at the interface of pathways controlling thrombosis and inflammation. Here, as one remarkable example, studies using a novel and highly selective pharmacologic inhibitor of the spleen tyrosine kinase Syk [PRT060318; 2-((1R,2S)-2-aminocyclohexylamino)-4-(m-tolylamino)pyrimidine-5-carboxamide] coupled with genetic experiments, demonstrate that Syk inhibition ameliorates both the acute and chronic responses to vascular injury without affecting hemostasis. Specifically, lack of Syk (murine radiation chimeras) attenuated shear-induced thrombus formation ex vivo, and PRT060318 strongly inhibited arterial thrombosis in vivo in multiple animal species while having minimal impact on bleeding. Furthermore, leukocyte-platelet–dependent responses to vascular injury, including inflammatory cell recruitment and neointima formation, were markedly inhibited by PRT060318. Thus, Syk controls acute and long-term responses to arterial vascular injury. The therapeutic potential of Syk may be exemplary of a new class of antiatherothrombotic agents that target the interface between thrombosis and inflammation.
Current Perspectives on Desmoid Tumors: The Mayo Clinic Approach
Joglekar, Siddharth, Rose, Peter S. , Sim, Franklin H. , Okuno, Scott H. , Petersen, Ivy A.

Mayo Clinic

Cancers | August 9, 2011 | Volume: 3 | Issue: 3 | Pages: 3143-3155

10.3390/cancers3033143 | PMID 24212949 Get It

Desmoid tumors are a rare group of locally aggressive, non malignant tumors of fibroblastic origin that can lead to significant morbidity due to local invasion. Despite advances in the understanding of these tumors, their natural history is incompletely understood and the optimal treatment is still a matter of debate. Local control is the main goal of treatment and there has been a change in philosophy regarding the management of these tumors from aggressive surgical resection to function preservation. A multidisciplinary approach is essential to plan local control with acceptable morbidity. The current Mayo Clinic algorithm for the treatment of these tumors is based on institutional experience and the available evidence in the literature: asymptomatic/non progressive lesions away from vital structures are managed with observation and regular imaging; primary or recurrent desmoid tumors which are symptomatic or progressive or near vital structures are managed with wide surgical resection when wide surgical margins are possible with minimal functional and cosmetic loss. When positive or close surgical margins are likely, surgical resection with adjuvant radiotherapy or definitive radiotherapy is preferred. If likely functional or cosmetic deficit is unacceptable, radiotherapy is the treatment of choice. Unresectable lesions are considered for radiotherapy, chemotherapy or newer modalities however an unresectable lesion associated with a painful, functionless, infected extremity is managed with an amputation.
Proximal femoral allograft-prosthesis composites in revision hip replacement
Sakellariou, Vasileios I. , Hanssen, Arlen D. , Sim, Franklin H. , Babis, George C. , O’Connor, Mary I.

Mayo Clinic

The Journal of Bone and Joint Surgery. British volume | March 1, 2010 | Volume: 92-B | Issue: 3 | Pages: 349-355

10.1302/0301-620x.92b3.23112 | PMID 20190304 Get It

We report the use of an allograft prosthetic composite for reconstruction of the skeletal defect in complex revision total hip replacement for severe proximal femoral bone loss. Between 1986 and 1999, 72 patients (20 men, 52 women) with a mean age of 59.9 years (38 to 78) underwent reconstruction using this technique. At a mean follow-up of 12 years (8 to 20) 57 patients were alive, 14 had died and one was lost to follow-up. Further revision was performed in 19 hips at a mean of 44.5 months (11 to 153) post-operatively. Causes of failure were aseptic loosening in four, allograft resorption in three, allograft nonunion in two, allograft fracture in four, fracture of the stem in one, and deep infection in five. The survivorship of the allograft-prosthesis composite at ten years was 69.0% (95% confidence interval 67.7 to 70.3) with 26 patients remaining at risk. Survivorship was statistically significantly affected by the severity of the pre-operative bone loss (Paprosky type IV; p = 0.019), the number of previous hip revisions exceeding two (p = 0.047), and the length of the allograft used (p = 0.005).
Keeping Raw Data in Context
Nagarajan, Rakesh, Nahm, Meredith, Sim, Ida , Chute, Christopher G. , Lehmann, Harold P. , Scheuermann, Richard H.

Mayo Clinic

Science | February 7, 2009 | Volume: 323 | Issue: 5915 | Pages: 713-713

10.1126/science.323.5915.713a | PMID 19197039 Get It